Italian Study Finds Neuro Side Effects Very Common after Covid Vax
I have been struck by the wide range of neurological syndromes I see in the office in patients who took one or more of the ill-advised Covid vaccines
Many times I wonder what the risk is from population studies? Is my practice similar to what is seen in the medical literature?
Salsone et al, reported from Milan, Italy, results from the NEURO-COVAX Study.
As a general reference, when there is a 20 percent or more excess risk, that is an odd’s ratio, relative risk, or hazard ratio of 1.20 or greater, it is clinically important.
The NEURO-COVAX-cohort included 19,108 vaccinated people: 15,368 with BNT162b2 (Pfizer), 2,077 with mRNA-1273, 1,651 with ChAdOx1nCov-19, and 12 with Ad26.COV2.S who were subsequently excluded.
Approximately 31.2 percent of the sample developed post-vaccination neurological complications, particularly with ChAdOx1nCov-19. A vulnerable clinical profile emerged, where over 40 percent of the symptomatic people showed comorbidities in their clinical histories.
Defining the neurological risk profile, we found an increased risk for ChAdOx1nCov-19 of tremors (vs. BNT162b2, OR: 5.12, 95 percent CI: 3.51-7.48); insomnia (vs. mRNA-1273, OR: 1.87, 95 percent CI: 1.02-3.39); muscle spasms (vs. BNT162b2, OR: 1.62, 95 percent CI: 1.08-2.46); and headaches (vs. BNT162b2, OR: 1.49, 95 percent CI: 0.96-1.57).
For mRNA-1273, there were increased risks of paresthesia (numbness and tingling) (vs. ChAdOx1nCov-19, OR: 2.37, 95 percent CI: 1.48-3.79); vertigo (vs. ChAdOx1nCov-19, OR: 1.68, 95 percent CI: 1.20-2.35); diplopia (double vision) (vs. ChAdOx1nCov-19, OR: 1.55, 95 percent CI: 0.67-3.57); and sleepiness (vs. ChAdOx1nCov-19, OR: 1.28, 95 percent CI: 0.98-1.67).
In the period that ranged from March to August 2021, no one was hospitalized and/or died of severe complications related to the primary series of two COVID-19 vaccines. Hospitalization or death after one shot was not captured.
In summary, a shocking 31.2 percent of respondents to this large dataset sustained neurologic injury after two injections with verified data in health registries.
Most of the risk estimates indicate the safety profile is unacceptable. It is alarming that all neurological societies to date still recommend COVID-19 vaccines and none have issued safety warnings on the products.
In my practice, I have found 3-12 months of McCullough Protocol Base Spike Detoxification (BSD) in addition to other drugs is a reasonable approach to these problems once serious intracranial pathology has been excluded.
The fundamental principle of degradation of the Spike protein appears to be pivotal to managing these clinical syndromes.
In my experience, additional agents including corticosteroids, gabapentin, NAC, nicotine, and low-dose naltrexone can help with symptoms, but without BSD, cannot resolve the problem.
See more here substack.com
Some bold emphasis added
Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.